Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zea Tan, Rui Yamaguchi, Hiromichi EbiClinical 2020 · DOI

Abstract

Our findings suggest that EMT is a cause of both intrinsic and acquired resistance by activating the PI3K pathway in the presence of KRAS G12C inhibitor.
BibTeX
@inproceedings{adachi2020epithelial,
  author = {Yuta Adachi and Kentaro Ito and Yuko Hayashi and Ryo Kimura and Tuan Zea Tan and Rui Yamaguchi and Hiromichi Ebi},
  title = {{Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer}},
  booktitle = {Clinical},
  year = {2020},
  doi = {10.1158/1078-0432.ccr-20-2077},
}

Loading related content...

Figure